Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medicine composite for treating vaginitis

A composition and vaginitis technology, applied in the field of pharmaceutical preparations, can solve the problems of affecting curative effect, frequent medication times, and low curative effect, so as to improve medication compliance, reduce medication frequency, and ensure effective treatment

Active Publication Date: 2011-08-31
SHENZHEN SOUTH CHINA PHARMA
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] 1) easy to leak
After the common preparation is used, it is easy to leak out under the action of vaginal secretions and excretions. On the one hand, the drug will be lost and the curative effect cannot be guaranteed. Finally, the lying position is adopted, which brings great inconvenience to the patient and reduces the patient's compliance with medication.
[0008] 2) frequent use of medication
Due to the problems of leakage and fast drug release, the drug has a short action time in the vagina and low curative effect. Therefore, in most cases, it needs to be used once a day for 7 to 10 consecutive days, and the frequency of administration is frequent.
Frequent and multiple medications lead to poor drug compliance of patients, and some even cannot guarantee to complete the entire course of treatment, which affects the curative effect

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicine composite for treating vaginitis
  • Medicine composite for treating vaginitis
  • Medicine composite for treating vaginitis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0073] Prescription composition:

[0074] Butoconazole Nitrate 2%

[0075] Poloxamer F127 17%

[0076] Carbomer 934 0.5%

[0077] Hypromellose K4M 1.5%

[0078] Methylparaben 0.15%

[0079] water balance

[0080] Preparation:

[0081] Take methyl paraben, add water to dissolve and stir evenly, add poloxamer, carbomer and hypromellose while stirring, place it at 4°C, after fully dissolved, add 200-mesh sieve Stir the butoconazole nitrate evenly, pack it into vaginal applicators, 5g each, and get it.

Embodiment 2

[0083] Prescription composition:

[0084] Butoconazole Nitrate 100mg

[0085] Hypromellose K4M 400mg

[0086] Carbomer 947 100mg

[0087] Macrogol 4000 200mg

[0088] Preparation:

[0089] 1. Take butoconazole nitrate and pass through a 200-mesh sieve, hypromellose, polyethylene glycol and carbomer respectively pass through a 80-mesh sieve, mix well, add 80% ethanol solution to make a suitable soft gel, and pass through a 18-mesh sieve Make granules and dry them at 40-50°C to obtain dry granules;

[0090] 2. Pass the dry granules through a 20-mesh sieve for granulation, add talcum powder (according to 1% of the total amount of granules) as a flow aid and lubricant, mix well, and measure the granule content;

[0091] 3. Press into tablets, each tablet contains 100 mg of butoconazole nitrate, ready to pack.

Embodiment 3

[0093] Prescription composition:

[0094] Butoconazole Nitrate 1%

[0095] Hydroxypropyl Beta Cyclodextrin 40%

[0096] Poloxamer F127 17%

[0097] Hypromellose K4M 2%

[0098] Methylparaben 0.5%

[0099] Propylparaben 0.5%

[0100] Edetate Disodium 0.01%

[0101] water balance.

[0102] Preparation:

[0103] Take butoconazole nitrate and hydroxypropyl beta cyclodextrin, add water and continue to stir to dissolve, add edetate disodium, methylparaben and propylparaben, stir to dissolve, add poloxa while stirring Mulberry and hypromellose are placed at 4°C, and after being fully dispersed, they are divided into vaginal applicators, 10g each, and ready to be obtained.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a medicine composite for treating vaginitis, comprising main medicine, matrix, bio-adhesive material, release rate regulator and other additives. The medicine composite for treating vaginitis has special bioadhesive and longer keeping time, reduces medicine leakage, prolongs contact time of medicine and vagina mucosa and ensures curative effect; the composite has special vagina slow release performance and can continuously release medicine for 2-7 days; compared with common preparation, the medicine composite prolongs medicine release time and can reduce medicine application times, thus bringing convenience for patients to apply the medicine. Meanwhile, because the medicine composite has the characteristics of bioadhesive and long efficiency of slow release and has no requirements for medicine application time, thus medicine application can be carried out at any time.

Description

technical field [0001] The invention relates to the technical field of pharmaceutical preparations, in particular to a pharmaceutical composition for treating vaginitis. Background technique [0002] Gynecological inflammation is a common disease in women. About 87% of adult women in the world have been infected with gynecological inflammation to varying degrees. Common clinical gynecological inflammations include vaginitis, cervicitis, pelvic inflammatory disease, endometritis, etc. Among them, the incidence of vaginitis The highest, accounting for about one-third of gynecological inflammation. Vaginitis is mainly divided into fungal vaginitis, bacterial vaginitis, and trichomonas vaginitis. Bacterial vaginosis and fungal vaginitis have the highest incidence rates. These two kinds of vaginitis have different incidence rates in different countries and regions. In the United States, the incidence rate of bacterial vaginosis is high, while in Europe, the incidence rate of fun...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K45/00A61K31/4174A61K31/496A61K31/4164A61K47/32A61K47/34A61K47/36A61K47/38A61K47/40A61K47/44A61P15/02A61K47/10
Inventor 巩洪刚邓文军常建晖郑国玲邓树海
Owner SHENZHEN SOUTH CHINA PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com